Panacea Biotec Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Agri-Tech (India) Ltd, Orbit Exports Ltd, Shardul Securities Ltd and Creative Eye Ltd are among the other losers in the BSE's 'B' group today, 10 June 2026.

Panacea Biotec Ltd crashed 9.99% to Rs 547.65 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 1.52 lakh shares were traded on the counter so far as against the average daily volumes of 75434 shares in the past one month.

Agri-Tech (India) Ltd tumbled 9.97% to Rs 122.8. The stock was the second biggest loser in 'B' group.On the BSE, 7168 shares were traded on the counter so far as against the average daily volumes of 2625 shares in the past one month.

Orbit Exports Ltd lost 9.47% to Rs 198. The stock was the third biggest loser in 'B' group.On the BSE, 936 shares were traded on the counter so far as against the average daily volumes of 1597 shares in the past one month.

Shardul Securities Ltd shed 9.02% to Rs 27.25. The stock was the fourth biggest loser in 'B' group.On the BSE, 1367 shares were traded on the counter so far as against the average daily volumes of 1775 shares in the past one month.

Creative Eye Ltd plummeted 7.95% to Rs 6.25. The stock was the fifth biggest loser in 'B' group.On the BSE, 116 shares were traded on the counter so far as against the average daily volumes of 2505 shares in the past one month.

Powered by Capital Market - Live News

Panacea Biotec announced the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll? in sub-Saharan Africa (sSA) and to facilitate its broader global use. The four-year initiative is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), supported by the European Union and aligns with the EDCTP3 mission to combat Neglected Tropical Diseases (NTDs), including dengue fever, and seeks to reduce the disease burden across Africa.

The DENSTAR project is coordinated by the ?Sclavo Vaccines Association?, a non-profit organization based in Siena (Italy) devoted to support vaccine research and development in developing countries. The DENSTAR consortium unites 10 Partners from 9 countries across Europe, Africa, the United States, India and South Korea which comprises of universities, research organizations, a biotech company and a non profit organization, bringing together experts, researchers, regulators, healthcare practitioners. Panacea Biotec being the developer of DengiAll?, a tetravalent dengue vaccine targeting all four virus serotypes and currently in late-stage development in India, is a key partner of the DENSTAR consortium. This diverse and complementary consortium embodies a great public-private partnership, fully aligned with the DENSTAR project's goal to promote broader use of DengiAll? in Africa and globally, contributing to equitable access to safe and effective dengue prevention tools.

Net profit of Panacea Biotec reported to Rs 0.52 crore in the quarter ended March 2026 as against net loss of Rs 1.89 crore during the previous quarter ended March 2025. Sales rose 25.82% to Rs 166.75 crore in the quarter ended March 2026 as against Rs 132.53 crore during the previous quarter ended March 2025.

For the full year,net loss reported to Rs 5.37 crore in the year ended March 2026 as against net loss of Rs 8.37 crore during the previous year ended March 2025. Sales rose 14.43% to Rs 639.77 crore in the year ended March 2026 as against Rs 559.09 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 29 May 2026.